# A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

> **NCT05098197** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Liver Cancers
- Tumor Infiltrating Lymphocyte
- Treatment Side Effects
- Effects of Immunotherapy
- Advanced Pancreatic Cancers

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocyte

## Key facts

- **NCT ID:** NCT05098197
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-26
- **Primary completion:** 2026-09-25
- **Final completion:** 2026-09-25
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-11

## Collaborators

- Shanghai 10th People's Hospital

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098197, "A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT05098197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*